Navigation Links
New therapeutic targets in the treatment of ulcerative colitis
Date:11/13/2007

Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years. Unfortunately, the etiology and pathogenesis of ulcerative colitis have not been clarified yet. Therefore, no effective etiological treatment is available at present. But a recent study published in issue 44 of the World Journal of Gastroenterology may offer new insight into this difficult-to-treat disease.

A research team from the First Affiliated Hospital of Dalian Medical University's Department of Gastroenterology, China, led by Professor Ying-De Wang, investigated the expression of matrix metalloproteinase-1 (MMP-1) and tumor necrosis factor- (TNF-alpha). MMP-1 is a peptidase that degrades the extracellular matrix in the colonic mucosa, while TNF-alpha is an important and harmful inflammatory cytokine produced in macrophages in colon. The research team found that both MMP-1 and TNF-alpha were over expressed in the colonic mucosa of patients with ulcerative colitis. The over expressed MMP-1 excessively degrades the extracellular matrix, and subsequently damages the colonic mucosa and causes ulceration and inflammatory changes in ulcerative colitis, and the over expressed TNF-alpha directly damages the colon mucosa. MP-1 and TNF-alpha proteins have the so-called synergistic action. The study revealed that the excessively expressed TNF-alpha stimulated MMPs secreting cells to produce more MMP-1, aggravating the mucosa damage. Meanwhile, MMP-1 promoted secretion of TNF-alpha in a positive feedback manner to cause further injury in the mucosa of colon. So it is very likely both MMP-1 and TNF-alpha play a central role in the development of ulcerative colitis.

Because of the important functions of MMP-1 and TNF-alpha in the development of ulcerative colitis, they have become therapeutic targeting proteins in the treatment of ulcerative colitis. It has been reported that agents of MMPs inhibitor and anti-TNF-alpha antibody were developed in Europe and America. For example, a TNF-alpha antagonist, Infliximab, has been shown to be effective against adult and child patients with ulcerative colitis. It has been approved by the FDA for clinical use in patients with Crohn's disease, another inflammatory bowel disease similar to ulcerative colitis. But MMPs inhibitor has only been used to treat experimental animal models of ulcerative colitis. The clinical application of MMPs inhibitor awaits future studies.

The results of this study will undoubtedly bring about a new round of research on the pathogenesis and new methods of treating ulcerative colitis. This will be a step toward a promising future in the battle against ulcerative colitis.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
86-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
Breaking Medicine Technology: